Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.67 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.57 |
| ▸ | NOS1 | P29475 | 2/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | OGT | O15294 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 2/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29771053 | 1.00 | KDM4E (0.67) | KDM4EALDH1A1CREBBPSMYD3NOS1 | |
| SCHEMBL2946079 | 0.87 | PDE3B (0.63) | KDM4EALDH1A1CREBBPSMYD3NOS1 | |
| SCHEMBL1421351 | 0.86 | NOS1 (0.56) | KDM4EALDH1A1CREBBPSMYD3NOS1 | |
| SCHEMBL2316982 | 0.84 | KDM4E (0.69) | KDM4EALDH1A1CREBBPSMYD3NOS1 | |
| SCHEMBL349741 | 0.84 | CREBBP (0.65) | KDM4EALDH1A1CREBBPSMYD3NOS1 | |
| SCHEMBL2546849 | 0.84 | CREBBP (0.69) | KDM4EALDH1A1CREBBPSMYD3NOS1 | |
| SCHEMBL6992123 | 0.84 | CREBBP (0.65) | KDM4EALDH1A1CREBBPSMYD3NOS1 | |
| SCHEMBL6992124 | 0.84 | CREBBP (0.60) | KDM4EALDH1A1CREBBPSMYD3NOS1 | |
| SCHEMBL13146791 | 0.84 | CREBBP (0.60) | KDM4EALDH1A1CREBBPSMYD3NOS1 | |
| SCHEMBL6647933 | 0.83 | ALDH1A1 (0.60) | KDM4EALDH1A1CREBBPSMYD3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | claimed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | claimed |
| CN-1759095-A | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARM INC (US) | 2006-04-12 | — | — | CN | claimed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | claimed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-12528797-B2 | Heterocyclic compounds for medical treatment | C4 THERAPEUTICS, INC. | 2026-01-20 | — | — | US | disclosed |
| US-12391690-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LIGACHEM BIOSCIENCES INC. (KR) | 2025-08-19 | — | — | US | disclosed |
| CN-114585360-B | Methods of using the same for treating epilepsy | 特维娜有限公司 | 2025-04-29 | — | — | CN | disclosed |
| EP-4470618-A2 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | C4 Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-1716100-A2 | THERAPEUTIC AMIDE DERIVATIVES | Pfizer, Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2006010966-A1 | NEW BENZOYL UREA DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
| US-6642256-B2 | Brain disorders, psychological disorders, antiischemic agents, central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2003-11-04 | — | — | US | disclosed |
| EP-1345935-A2 | PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS | Warner-Lambert Company LLC (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030018021-A1 | Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists | KORNBERG BRIAN EDWARD (US) | 2003-01-23 | — | — | US | disclosed |
| WO-2002050070-A2 | PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528797-B2 | Heterocyclic compounds for medical treatment | CRBN, CUL2, ADRM1 | KDM4E 1402/4885ALDH1A1 2849/4885CREBBP 411/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | KDM4E 3565/4885ALDH1A1 587/4885CREBBP 2825/4885 |
| US-12391690-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | ENPP2, PLA2G10, LPCAT1 | KDM4E 3095/4885ALDH1A1 4207/4885CREBBP 3867/4885 |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | KDM4E 4309/4885ALDH1A1 527/4885CREBBP 2749/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | KDM4E 4082/4885ALDH1A1 2133/4885CREBBP 898/4885 |
| US-20030018021-A1 | Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists | GRIN1, OPRD1, OPRM1 | KDM4E 2119/4885ALDH1A1 445/4885CREBBP 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.